9.4 Pharmacoeconomics & Formulary Decision Making

Why the Exam Tests Pharmacoeconomics

The DHA CBT Guideline names Karen Rascati, Essentials of Pharmacoeconomics among the official reference texts for PHO5481. No content-area bullet is called "pharmacoeconomics", so the material surfaces inside Pharmaceutical Care and Disease State Management: formulary choices, generic substitution decisions, and justifying a therapy to a payer. In UAE community and hospital practice this is daily work - most patients are covered by mandatory health insurance (DHA's scheme in Dubai), formularies are insurer-specific, and the pharmacist is usually the person who has to reconcile a prescriber's choice with what the plan will fund.

Exam items here are conceptual, not computational. You are asked to name the analysis that fits a scenario, read a simple cost-effectiveness comparison, or identify which perspective a stated cost belongs to.

The Four Core Analyses

All four compare costs (always in money) against consequences; they differ only in how the consequences are measured.

The distinguishing question in an exam stem is always what unit is the outcome in? Money on both sides means CBA. QALYs mean CUA. A clinical unit means CEA. "Assume the outcomes are identical" means CMA - and CMA is only legitimate when that equivalence has actually been demonstrated, which is why it is the correct analysis for a generic-substitution decision and the wrong one for comparing two different drug classes.

Reading an ICER

The incremental cost-effectiveness ratio (ICER) is the single calculation you should be able to do:

ICER = (Cost of A - Cost of B) / (Effect of A - Effect of B)

Worked example. A new anticoagulant costs AED 4,800 per patient-year and prevents 0.030 strokes per year. Warfarin plus INR monitoring costs AED 1,200 per patient-year and prevents 0.018 strokes per year.

• Incremental cost = 4,800 - 1,200 = AED 3,600
• Incremental effect = 0.030 - 0.018 = 0.012 strokes prevented
• ICER = 3,600 / 0.012 = AED 300,000 per stroke prevented

The number is meaningless on its own. It becomes a decision only against a willingness-to-pay threshold set by the payer, and against the cost of the strokes avoided. A therapy that is both cheaper and more effective is dominant and needs no ICER at all; one that is dearer and less effective is dominated and is rejected outright.

Cost Categories and Perspective

Which costs count depends entirely on whose books you are looking at - and stating the perspective is the first thing a well-posed pharmacoeconomic question does.

• Direct medical costs: the drug, the dispensing fee, the INR clinic visit, the hospital bed for a bleed.
• Direct non-medical costs: the patient's taxi to the anticoagulation clinic, a carer's parking.
• Indirect costs: productivity lost while the patient is off work.
• Intangible costs: pain, anxiety, reduced quality of life - real, but hard to price, which is why CUA captures them through QALYs instead.

From an insurer's perspective only direct medical costs it reimburses count. From a societal perspective all four count, which is why a drug that looks expensive to a payer can be cost-saving to society once lost working days are included. A stem that says "from the perspective of the health insurer" is telling you to ignore the productivity figures it also supplies - a standard distractor.

The Pharmacist's Practical Role

• Generic substitution is the highest-volume pharmacoeconomic act in a UAE pharmacy. It is a cost-minimisation decision, and it is only valid where bioequivalence holds - which is exactly why narrow-therapeutic-index products such as levothyroxine, warfarin, ciclosporin and antiepileptics are handled cautiously (Section 13.2).
• Adherence is an economic intervention. A medicine that is not taken delivers zero effect at full cost, so counselling that converts a non-adherent patient into an adherent one improves cost-effectiveness more reliably than switching molecules.
• Avoided costs are the argument. When justifying a therapy to a payer, the persuasive figure is rarely the drug price - it is the admission, the bleed, the amputation, or the exacerbation that does not happen.
• Cheapest is not the same as most cost-effective. A low-acquisition-cost drug that requires frequent monitoring, causes more adverse events, or is poorly tolerated can carry the higher total cost of care.